Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.

ABSTRACT:

Importance

Thyroid eye disease can be a debilitating autoimmune disorder characterized by progressive proptosis or diplopia. Teprotumumab has been compared with placebo in randomized clinical trials, but not with intravenous methylprednisolone (IVMP), which sometimes is used in clinical practice for this condition.

Objective

To conduct a matching-adjusted indirect comparison of teprotumumab vs IVMP vs placebo.

Data sources

Deidentified patient-level data from teprotumumab trials and aggregate-level data from literature on the most recommended regimen of IVMP.

Study selection

PubMed and Embase were searched for randomized/observational studies using key terms and controlled vocabulary. Full texts of eligible articles were reviewed and cataloged.

Data extracti

SUBMITTER: Douglas RS 

PROVIDER: S-EPMC8855315 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature